




INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 25 November 2004

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)



1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

17 DEC 2003

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

MG/DAB/PB60626P

2. Patent application number

(The Patent Office will fill in his part)

0329214.1

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

00473587008
United Kingdom

4. Title of the invention

Novel Compounds

5. Name of your agent (*if you have one*)

"Address for service" in the United Kingdom
to which all correspondence should be sent
(*including the postcode*)

Patents ADP number (*if you know it*)

08072555006

Corporate Intellectual Property

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (*if you know it*) the or each application number

| Country | Priority application number (<i>if you know it</i>) | Date of filing (<i>day / month / year</i>) |
|---------|--|---|
|---------|--|---|

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

| Number of earlier application | Date of filing (<i>day / month / year</i>) |
|-------------------------------|---|
|-------------------------------|---|

8. Is a statement of inventorship and of right

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form
Description
Claim(s)
Abstract
Drawings

18
2 

10. If you are also filing any of the following,
state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination
and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(*please specify*)

11.

We request the grant of a patent on the basis of this
application

Signature


M Gibson

Date 17-Dec-03

12. Name and daytime telephone number of
person to contact in the United Kingdom

M Gibson 01279 644841

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be*

NOVEL COMPOUNDS


The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

JP 2001226269 and WO 00/23437 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives which are claimed to be useful in the treatment of obesity. DE 2207430, US 4,210,749 and FR 2171879 (Pennwalt Corp) and GB 1268243 (Wallace and Tiernan Inc) all describe a series of benzazepine derivatives which are claimed as being antagonists for narcotics (such as morphine or codeine) and also anti-histamines and anticholinergic agents. WO 02/14513 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives with GPR12 activity which are claimed to be useful in the treatment of attention deficit disorder, narcolepsy or anxiety. WO 02/02530 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives as GPR14 antagonists which are claimed to be useful in the treatment of hypertension, atherosclerosis and cardiac infarction. WO 01/03680 (Isis Innovation Ltd) describe a series of benzazepine derivatives which are claimed as effective agents in the preparation of cells for transplantation in addition to the inhibition of diseases such as diabetes. WO 00/21951 (SmithKline Beecham plc) discloses a series of tetrahydrobenzazepine derivatives as modulators of dopamine D3 receptors which are claimed to be useful as antipsychotic agents. WO 01/87834 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives as MCH antagonists which are claimed to be useful in the treatment of obesity. WO 02/15934 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives as urotensin II receptor antagonists which are claimed to be useful in the treatment of neurodegenerative disorders.

The histamine H3 receptor is predominantly expressed in the mammalian central nervous system (CNS), with minimal expression in peripheral tissues except on some sympathetic nerves (Leurs *et al.*, (1998), Trends Pharmacol. Sci. **19**, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic and cholinergic neurons (Schlicker *et al.*, (1994), Fundam. Clin. Pharmacol. **8**, 128-137). Additionally, *in vitro* and *in vivo* studies have shown that H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera *et al.*, (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp255-267, Elsevier Science B.V.). Moreover, a number of reports in the literature have demonstrated the cognitive enhancing properties of H3 antagonists (e.g. thioperamide, clobenpropit, ciproxifan and GT-2331) in rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni *et al.*, (1999), Behav. Brain Res. **104**, 147-155). These data suggest that novel H3 antagonists and/or inverse agonists such as the current series could be useful for the

treatment of cognitive impairments in neurological diseases such as Alzheimer's disease and related neurodegenerative disorders.

The present invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ represents -C₃₋₇ cycloalkyl optionally substituted by C₁₋₃ alkyl;

R² represents hydrogen, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -aryl, -heterocyclyl, -heteroaryl, -C₃₋₈ cycloalkyl-Y-C₃₋₈ cycloalkyl, -C₃₋₈ cycloalkyl-Y-aryl, -C₃₋₈ cycloalkyl-Y-heteroaryl, -C₃₋₈ cycloalkyl-Y-heterocyclyl, -aryl-Y-C₃₋₈ cycloalkyl, -aryl-Y-aryl, -aryl-Y-heteroaryl, -aryl-Y-heterocyclyl, -heteroaryl-Y-C₃₋₈ cycloalkyl, -heteroaryl-Y-aryl, -heteroaryl-Y-heteroaryl, -heteroaryl-Y-heterocyclyl, -heterocyclyl-Y-C₃₋₈ cycloalkyl, -heterocyclyl-Y-aryl, -heterocyclyl-Y-heteroaryl, -heterocyclyl-Y-heterocyclyl;

X represents a bond, CO, SO₂, CONR⁵ or COO;

Y represents a bond, C₁₋₆ alkyl, CO, CONH, NHCO, O, SO₂, SO₂NH or NHSO₂;

R³ represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl;

R⁴ and R⁵ independently represent hydrogen, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -aryl, -heterocyclyl or -heteroaryl;

n is 0, 1 or 2;

wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R², R³ and R⁴ may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C₁₋₆ alkyl, pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, aryloxy, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamino, C₁₋₆ alkylamido, -R⁵, -CO₂R⁵, -COR⁵, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group -NR⁶R⁷, -C₁₋₆ alkyl-NR⁶R⁷, -C₃₋₈ cycloalkyl-NR⁶R⁷, -CONR⁶R⁷, -NR⁶COR⁷, -NR⁶SO₂R⁷, -OCONR⁶R⁷, -NR⁶CO₂R⁷, -NR⁵CONR⁶R⁷ or -SO₂NR⁶R⁷ (wherein R⁵, R⁶ and R⁷ independently represent hydrogen, C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, aryl, heterocyclyl or heteroaryl or -NR⁶R⁷ may represent a nitrogen containing heterocyclyl group, wherein said R⁵, R⁶ and R⁷ groups may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are

selected from the group consisting of halogen, hydroxy, C₁₋₈ alkyl, C₁₋₆ alkoxy, cyano, amino, =O or trifluoromethyl); or solvates thereof.

- 5 Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C₁₋₄ alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
- 10 References to 'aryl' include references to monocyclic carbocyclic aromatic rings (eg. phenyl) and bicyclic carbocyclic aromatic rings (e.g. naphthyl) or carbocyclic benzofused rings (eg. C₃₋₈ cycloalkyl fused to a phenyl ring, such as dihydroindenyl or tetrahydronaphthalenyl).
- 15 The term "heterocyclyl" is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated aliphatic ring or a 4-7 membered saturated or partially unsaturated aliphatic ring fused to a benzene ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Suitable examples of such monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, diazepanyl, azepanyl, imidazolidinyl, isothiazolidinyl, oxazolidinyl, pyrrolidinone and
- 20 tetrahydro-oxazepinyl. Suitable examples of benzofused heterocyclic rings include indolinyl, isoindolinyl, benzodioxolyl, dihydroisoindole, dihydrobenzofuranyl, dihydrobenzothiopyranyl and dihydroisoquinolinyl.
- 25 The term "heteroaryl" is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-11 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, pyridyl and tetrahydropyranyl.
- 30 Suitable examples of such fused aromatic rings include benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, furopyridinyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.
- 35 Preferably, R¹ represents -C₃₋₇ cycloalkyl (eg. cyclobutyl, cyclopentyl or cyclohexyl) optionally substituted by a C₁₋₃ alkyl (eg. methyl) group.
- Most preferably, R¹ represents unsubstituted cyclobutyl or cyclopentyl, especially
- 40 unsubstituted cyclobutyl.

Preferably, R² represents

- C₁₋₆ alkyl (eg. methyl);
- C₃₋₈ cycloalkyl (eg. cyclopropyl);
- aryl (eg. -phenyl) optionally substituted by a cyano group;
- heteroaryl (eg. -pyridinyl) optionally substituted by a -CONR⁵R⁶ group;
- heterocyclyl (eg. -morpholinyl or -tetrahydropyranyl); or
- aryl-Y-heteroaryl (eg. -phenyl-pyridinyl).

More preferably, R² represents -aryl (eg. -phenyl) optionally substituted by a cyano group or -aryl-Y-heteroaryl (eg. -phenyl-pyridinyl), particularly -aryl-Y-heteroaryl (eg. -phenyl-pyridinyl).

Preferably, X represents CO or SO₂, more preferably CO.

Preferably, Y represents a bond.

Preferably, R⁴ represents hydrogen.

Preferably, R⁵ and R⁶ independently represent hydrogen and C₁₋₆ alkyl (eg. methyl).

Preferably, n represents 0 or 1, more preferably 0.

When n represents 1, R³ is preferably a halogen (eg. iodine) atom or a cyano group.


Preferred compounds according to the invention include examples E1-E8 as shown below, or a pharmaceutically acceptable salt thereof.

Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphate, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention.

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

- (a) preparing a compound of formula (I) wherein X represents CO which comprises reacting a compound of formula (II)



wherein R^1 , R^3 , R^4 and n are as defined above, with a compound of formula $R^2\text{-CO}_2\text{H}$, wherein R^2 is as defined above for R^2 or a group convertible thereto; or

(b) preparing a compound of formula (I) wherein X represents CO which comprises reacting a compound of formula (II) as defined above, with an activated compound of formula $R^2\text{-COL}^1$ wherein R^2 is as defined above for R^2 or a group convertible thereto and L^1 represents a suitable leaving group such as a halogen atom (eg. chlorine, bromine) or imidazole; or

(c) preparing a compound of formula (I) wherein X represents CONR^5 which comprises reacting a compound of formula (II) as defined above, with an activated compound of formula $R^2\text{-NR}^5\text{COL}^2$ wherein R^2 and R^5 are as defined above for R^2 and R^5 , respectively or a group convertible thereto and L^2 represents a suitable leaving group such as a halogen atom (eg. chlorine, bromine); or


(d) preparing a compound of formula (I) wherein X represents SO_2 which comprises reacting a compound of formula (II) as defined above, with an activated compound of formula $R^2\text{-SO}_2\text{L}^3$ wherein R^2 is as defined above for R^2 or a group convertible thereto and L^3 represents a suitable leaving group such as a halogen atom (eg. chlorine, bromine); or

(e) preparing a compound of formula (I) wherein X represents CONR^5 which comprises reacting a compound of formula (II) as defined above, with a compound of formula $R^2\text{-N=C=O}$ wherein R^2 is as defined above for R^2 or a group convertible thereto; or

(f) preparing a compound of formula (I) wherein X represents COO which comprises reacting a compound of formula (II) as defined above, with an activated compound of formula $R^2\text{-OCOL}^4$ wherein R^2 is as defined above for R^2 or a group convertible thereto and L^4 represents a suitable leaving group such as a halogen atom (eg. chlorine, bromine); or

(g) preparing a compound of formula (I) wherein X represents a bond which comprises reacting a compound of formula (II) as defined above, with a compound of formula $R^2\text{-L}^5$, wherein R^2 is as defined above for R^2 or a group convertible thereto and L^5 represents a suitable leaving group such as a halogen atom (eg. chlorine, bromine or iodine);

(h) reacting a compound of formula (III)



wherein R^2 , R^3 , R^4 , X and n are as defined above, with a compound of formula $R^{1'}-L^6$, wherein $R^{1'}$ is as defined above for R^1 or a group convertible thereto and L^6 represents a suitable leaving group such as a halogen atom (eg. bromine, iodine or tosylate); or

(i) reacting a compound of formula (III) as defined above, with a ketone of formula $R^{1'}=O$, wherein $R^{1'}$ is as defined above for R^1 or a group convertible thereto; or

(j) deprotecting a compound of formula (I) which is protected; and

(k) interconversion to other compounds of formula (I).

Process (a) typically comprises the use of a coupling reagent, such as dicyclohexylcarbodiimide, in an appropriate solvent such as dichloromethane or dimethylformamide, optionally in the presence of a suitable activating agent, such as hydroxybenzotriazole at an appropriate temperature such as room temperature.

Processes (b), (c), (d) and (f) typically comprise the use of a base, such as triethylamine, in an appropriate solvent such as dichloromethane, at an appropriate temperature, for example room temperature.

Process (e) may typically be performed in a suitable solvent, such as dichloromethane, at an appropriate temperature, for example room temperature.

When the leaving group L^5 is attached to an sp^3 hybridised carbon, for example, $R^{2'}-L^5$ is an alkyl halide, process (g) typically comprises the use of a suitable base, such as potassium hydroxide in an appropriate solvent such as methanol optionally in the presence of a catalyst such as potassium iodide at an appropriate temperature such as reflux.

When the leaving group L^5 is attached to an sp^2 hybridised carbon, for example, $R^{2'}-L^5$ is an aryl or heteroaryl halide, process (g) typically comprises the use of a transition metal catalyst, such as a palladium salt (eg. Palladium (II) acetate), in combination with a suitable ligand, such as a BINAP, in the presence of a base such as potassium carbonate, in an appropriate solvent such as toluene, at an appropriate temperature such as reflux.


Process (h) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of a catalyst such as potassium iodide at an appropriate temperature such as reflux.

- 5 Process (i) typically comprises the use of reductive conditions (such as treatment with a borohydride eg. sodium triacetoxyborohydride), optionally in the presence of an acid, such as acetic acid, in an appropriate solvent such as dichloromethane at a suitable temperature such as room temperature.
- 10 In process (j), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in
- 15 dioxan or trifluoroacetic acid in dichloromethane) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl (-COCF₃) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker),
- 20 which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.

- Process (k) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis, amide bond formation or transition metal mediated coupling
- 25 reactions. Examples of transition metal mediated coupling reactions useful as interconversion procedures include the following: Palladium catalysed coupling reactions between organic electrophiles, such as aryl halides, and organometallic reagents, for example boronic acids (Suzuki cross-coupling reactions); Palladium catalysed amination and amidation reactions between organic electrophiles, such as aryl halides, and
- 30 nucleophiles, such as amines and amides; Copper catalysed amidation reactions between organic electrophiles (such as aryl halides) and nucleophiles such as amides; and Copper mediated coupling reactions between phenols and boronic acids.
- may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester
- 35 hydrolysis, amide bond formation or transition metal mediated coupling reactions. Examples of transition metal mediated coupling reactions useful as interconversion procedures include the following: Palladium catalysed coupling reactions between organic electrophiles, such as aryl halides, and organometallic reagents, for example boronic acids (Suzuki cross-coupling reactions); Palladium catalysed amination and amidation reactions
- 40 between organic electrophiles, such as aryl halides, and nucleophiles, such as amines and amides; Copper catalysed amidation reactions between organic electrophiles (such as aryl

halides) and nucleophiles such as amides; and Copper mediated coupling reactions between phenols and boronic acids.

- 5 Compounds of formula (II) wherein R^4 represents hydrogen may be prepared in accordance with the following scheme




wherein R^1 , R^1' , R^3 and n are as defined above.

- 10 Step (i) can be performed under reducing conditions in an analogous manner to that described for process (i) above.

Step (ii) comprises a reduction reaction, for example reaction of a compound of formula (V) with hydrogen in the presence of a catalyst, for example palladium in methanol.

- 15 Compounds of formula (II) wherein R^4 represents $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, -aryl, -heterocyclyl or -heteroaryl may be prepared in accordance with the following scheme:




wherein R^1 , R^3 and n are as defined above and L^7 represents a suitable leaving group such as a halogen atom (eg. bromine or iodine).

Step (i) may be performed under reducing conditions in an analogous manner to that described for process (i) above.

When the leaving group L^7 is attached to an sp^3 hybridised carbon, for example, R^4-L^7 is an alkyl halide, step (ii) typically comprises the use of a suitable base, such as potassium hydroxide in an appropriate solvent such as methanol at an appropriate temperature such as reflux.

When the leaving group L^7 is attached to an sp^2 hybridised carbon, for example, R^4-L^7 is an aryl or heteroaryl halide, step (ii) typically comprises the use of a transition metal catalyst, such as a palladium salt (eg. Palladium (II) acetate), in combination with a suitable ligand, such a BINAP, in the presence of a base such as potassium carbonate, in an appropriate solvent such as toluene, at an appropriate temperature such as reflux.

Compounds of formula (III) wherein R^4 represents hydrogen may be prepared in accordance with the following scheme:



wherein R^2 , R^3 , X and n are as defined above and P^1 represents a suitable protecting group such as Boc.

Step (i) comprises a reduction reaction, for example reaction of a compound of formula (VI) with hydrogen in the presence of a catalyst, for example palladium in methanol.

Step (ii) can be performed as highlighted in processes (a - g).

Step (iii) comprises a deprotection reaction and may be performed according to the process (j).

Compounds of formula (IV) may be prepared in accordance with procedures shown in WO 03/68752.

- 5 Compounds of formula (VI) may be prepared in accordance with procedures shown in WO 03/68751.

10 Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychiatric disorders including schizophrenia (particularly cognitive deficit of schizophrenia), attention deficit hyperactivity disorder, depression and addiction; and other diseases including obesity, asthma, allergic rhinitis, nasal congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders.

20 Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular cognitive impairments in diseases such as Alzheimer's disease and related neurodegenerative disorders.

25 The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

30 In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.

35 When used in therapy, the compounds of formula (I) are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.

40 Thus, the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

- 5 Compounds of formula (I) may be used in combination with other therapeutic agents, for example histamine H1 antagonists or medicaments claimed to be useful as either disease modifying or symptomatic treatments of Alzheimer's disease. Suitable examples of such other therapeutic agents may be agents known to modify cholinergic transmission such as 5-HT₆ antagonists, M1 muscarinic agonists, M2 muscarinic antagonists or
10 acetylcholinesterase inhibitors. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

- 15 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

- 20 The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

- 25 When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

- 30 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are
35 generally preferred.

- 40 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.


For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

Description 1

3-Cyclobutyl-7-nitro-2,3,4,5-tetrahydro-1H-3-benzazepine (D1)




Sodium triacetoxyborohydride (320 mg, 1.5 mmol) was added to a stirred solution of 7-nitro-2,3,4,5-tetrahydro-1H-3-benzazepine (EP285323) (192 mg, 1 mmol), cyclobutanone (105 mg, 1.5 mmol) in dichloromethane (10 ml). After 1 hour at room temperature the reaction mixture was diluted with dichloromethane (100 ml) and washed with a saturated solution of sodium bicarbonate, water and brine. The organic layer was dried (sodium

sulfate), filtered and concentrated *in vacuo* to afford the title compound (D1). MS (ES+) m/e 247 $[M+H]^+$.

Description 2


5 3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine (D2)



3-Cyclobutyl-7-nitro-2,3,4,5-tetrahydro-1H-3-benzazepine (D1) (2 g) was dissolved in methanol (2 ml) and tetrahydrofuran (30 ml). Palladium (200 mg, 10% on charcoal paste) was added and the reaction mixture was stirred at room temperature under hydrogen (1
10 atmosphere) for 5 hours. The reaction mixture was filtered through celite and the filtrate concentrated *in vacuo* to afford the title compound (D2). MS (ES+) m/e 217 $[M+H]^+$.

Description 3

15 1,1-Dimethylethyl 7-[(4-morpholinylcarbonyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate (D3)




1,1-Dimethylethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate (PCT Int. Appl. (1998), WO 98/30560) (393 mg, 1.5 mmol) was stirred in dichloromethane (5ml) with diethylaminomethyl polystyrene (3.2 mmol/g, 1.00 g, 3.2 mmol). Morpholine carbamoyl
20 chloride (0.27 ml, 1.8 mmol) was added and the mixture stirred at room temperature for 16 hours. The resin was filtered, washed with dichloromethane and the filtrate concentrated *in vacuo*. The residue was purified by column chromatography (dichloromethane to 1:9:90 .880 ammonia: ethanol: dichloromethane) to afford the title compound (D3). MS (ES+) m/e 374 $[M-H]^-$.


25

Description 4


N-(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)-4-morpholinecarboxamide (D4)



1,1-Dimethylethyl-7-[(4-morpholinylcarbonyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepine-
30 3-carboxylate (D3) (562 mg, 1.5 mmol) was dissolved in dichloromethane (10 ml) and treated with trifluoroacetic acid (5 ml). The solution was stirred at room temperature for 1 hour, concentrated *in vacuo* and then twice co-evaporated with dichloromethane. The residue was dissolved in methanol and applied to a SCX (Varian bond-elute, 10g) and washed with methanol and then a mixture of .880 ammonia/ methanol. The combined basic
35 fractions were concentrated *in vacuo* and the residue purified by column chromatography (1:9:40 .880 ammonia: ethanol: dichloromethane) to afford the title compound (D4). MS (ES+) m/e 254 $[M+H]^+$.

Example 1***N*-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)-4-morpholinecarboxamide (E1)**

5 *N*-(2,3,4,5-Tetrahydro-1*H*-3-benzazepin-7-yl)-4-morpholinecarboxamide (D4) (250mg, 0.9mmol) was dissolved in 1% acetic acid in methanol (20ml) at 0 °C and treated dropwise with cyclobutanone (95mg, 1.35mmol). The mixture was stirred for 30 minutes and then (polystyrylmethyl)trimethylammonium borohydride (2mmol/g, 900mg, 1.8mmol) was added portion wise. The reaction mixture was stirred at room temperature for 18 hours, applied to a SCX (Varian bond-elute, 10g) and washed with methanol and then a mixture of .880 ammonia/ methanol. The combined basic fractions concentrated *in vacuo* and the residue purified by column chromatography eluting with a mixture of .880 ammonia: ethanol: dichloromethane (2:18:80) to afford the title compound (E1). MS (ES+) *m/e* 330 [M+H]⁺.

Example 2**4-Cyano-*N*-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)benzamide (E2)**


3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-amine (D2) (162mg, 0.75mmol) was stirred in dichloromethane (12ml) with diethylaminomethyl polystyrene (3.2mmol/g, 70mg, 2.25 mmol). 4-Cyanobenzoyl chloride (149mg, 0.9mmol) was added and the mixture stirred at room temperature for 1 hour. The reaction was diluted with methanol (10ml) and applied to a SCX ion exchange cartridge (Varian bond-elute, 10g), washed with methanol and then a mixture of .880 ammonia:methanol (1:9). The combined basic fractions were concentrated *in vacuo* and the residue purified by column chromatography .880 ammonia: ethanol: dichloromethane (2:18:80) to afford the title compound (E2). MS (ES+) *m/e* 346 [M+H]⁺.

Examples 3-5


Examples 3-5 (E3-5) were prepared using an analogous method to that described for Example 2 (E2) from the appropriate acid chloride indicated in the table:

| Example | Acid Chloride | LC/MS (M+H ⁺) |
|--|---|---------------------------|
| <i>N</i> -(3-Cyclobutyl-2,3,4,5-tetrahydro-1 <i>H</i> -3-benzazepin-7-yl)tetrahydro-2 <i>H</i> -pyran-4-carboxamide (E3) | Tetrahydro-2 <i>H</i> -pyran-4-carbonyl chloride (<i>Helv. Chim. Acta.</i> 1997, 80(5), 1528) | 329 |
| <i>N</i> -(3-Cyclobutyl-2,3,4,5-tetrahydro-1 <i>H</i> - | Acetyl chloride | 259 |


| | | |
|---|---------------------------------|-----|
| 3-benzazepin-7-yl)acetamide (E4) | | |
| <i>N</i> -(3-Cyclobutyl-2,3,4,5-tetrahydro-1 <i>H</i> -3-benzazepin-7-yl)cyclopropanecarboxamide (E5) | Cyclopropane carbonyl chloride. | 285 |

Example 6***N*-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)methanesulfonamide (E6)**

- 5 3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-amine (D2) (151mg, 0.75mmol) was stirred in dichloromethane (3ml). Methane sulfonyl chloride (103mg, 0.9mmol) was added and the mixture stirred at room temperature for 1 hour. Methanol (1ml) was added and the reaction was stirred for a further 0.5 hours then concentrated *in vacuo*. The crude mixture was triturated with diethyl ether, filtered and the solid was redissolved in methanol and
- 10 concentrated *in vacuo* to afford the title compound (E6). MS (ES+) *m/e* 295 [M+H]⁺.

Example 7**6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)amino]-*N*-methyl-3-pyridinecarboxamide (E7)**

- 15 Palladium (II) acetate (11mg, 0.05mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-amine (D2) (216mg, 1.0mmol), 6-chloro-*N*-methyl-3-pyridinecarboxamide (PCT Int. Appl. (2002), WO 02/0246186) (108mg, 1mmol), (±)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (31mg, 0.05mmol) and potassium carbonate (276mg, 2mmol) in toluene (14ml). The reaction mixture was heated at reflux for 4 hours, cooled to
- 20 room temperature and applied to a SCX ion exchange cartridge (Varian bond-elute, 10g), washed with methanol and then a mixture of .880 ammonia:methanol. The combined basic fractions were concentrated *in vacuo* and the residue purified by column chromatography .880 ammonia: ethanol: dichloromethane (1:9:90) to afford the title compound (E7). MS
- 25 (ES+) *m/e* 346 [M+H]⁺.

Example 8***N*-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)-4-(2-pyridinyl)benzamide (E8)**

- 30 A mixture 4-(2-pyridinyl)benzoic acid (219 mg, 1.1 mmol), 1-hydroxybenzotriazole hydrate (297 mg, 2.2 mmol) and *N*-cyclohexylcarbodiimide-*N*'-methyl polystyrene (1.3 g, 2.2 mmol, resin loading 1.8mmol/g) in dimethylformamide (5ml) was stirred at room temperature for

30 minutes. A solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-amine (D2) (200 mg, 0.9 mmol) in dimethylformamide (3ml) was added and the mixture stirred at room temperature for 18 hours. The mixture was filtered through an SCX ion exchange column eluting with methanol followed by 2.0 M ammonia solution in methanol to elute the product.

5 The residue was purified by silica gel chromatography eluting with a 1:9:90 mixture of 0.880 ammonia solution:methanol:dichloromethane to afford the title compound (E8) (199 mg, 54%); MS(ES+) *m/e* 398 [M+H]⁺.

Biological Data

10 A membrane preparation containing histamine H3 receptors may be prepared in accordance with the following procedures:

(i) Generation of histamine H3 cell line

DNA encoding the human histamine H3 gene (Huvar, A. *et al.* (1999) Mol. Pharmacol.

15 55(6), 1101-1107) was cloned into a holding vector, pCDNA3.1 TOPO (InVitrogen) and its cDNA was isolated from this vector by restriction digestion of plasmid DNA with the enzymes BamH1 and Not-1 and ligated into the inducible expression vector pGene (InVitrogen) digested with the same enzymes. The GeneSwitch™ system (a system where in transgene expression is switched off in the absence of an inducer and switched on in the presence of an inducer) was performed as described in US Patent nos: 5,364,791; 5,874,534; and 5,935,934. Ligated DNA was transformed into competent DH5α E. coli host bacterial cells and plated onto Luria Broth (LB) agar containing Zeocin™ (an antibiotic which allows the selection of cells expressing the sh ble gene which is present on pGene and pSwitch) at 50μg ml⁻¹. Colonies containing the re-ligated plasmid were identified by restriction analysis. DNA for transfection into mammalian cells was prepared from 250ml cultures of the host bacterium containing the pGeneH3 plasmid and isolated using a DNA preparation kit (Qiagen Midi-Prep) as per manufacturers guidelines (Qiagen).

25 CHO K1 cells previously transfected with the pSwitch regulatory plasmid (InVitrogen) were seeded at 2x10⁶ cells per T75 flask in Complete Medium, containing Hams F12 (GIBCOBRL, Life Technologies) medium supplemented with 10% v/v dialysed foetal bovine serum, L-glutamine, and hygromycin (100μg ml⁻¹), 24 hours prior to use. Plasmid DNA was transfected into the cells using Lipofectamine plus according to the manufacturers guidelines (InVitrogen). 48 hours post transfection cells were placed into complete medium supplemented with 500μg ml⁻¹ Zeocin™.

35 10-14 days post selection 10nM Mifepristone (InVitrogen), was added to the culture medium to induce the expression of the receptor. 18 hours post induction cells were detached from the flask using ethylenediamine tetra-acetic acid (EDTA; 1:5000; InVitrogen), following several washes with phosphate buffered saline pH 7.4 and resuspended in Sorting Medium containing Minimum Essential Medium (MEM), without phenol red, and supplemented with Earles salts and 3% Foetal Clone II (Hyclone). 40 Approximately 1x 10⁷ cells were examined for receptor expression by staining with a rabbit polyclonal antibody, 4a, raised against the N-terminal domain of the histamine H3

receptor, incubated on ice for 60 minutes, followed by two washes in sorting medium. Receptor bound antibody was detected by incubation of the cells for 60 minutes on ice with a goat anti rabbit antibody, conjugated with Alexa 488 fluorescence marker (Molecular Probes). Following two further washes with Sorting Medium, cells were filtered through a 50µm Filcon™ (BD Biosciences) and then analysed on a FACS Vantage SE Flow Cytometer fitted with an Automatic Cell Deposition Unit. Control cells were non-induced cells treated in a similar manner. Positively stained cells were sorted as single cells into 96-well plates, containing Complete Medium containing 500µg ml⁻¹ Zeocin™ and allowed to expand before reanalysis for receptor expression via antibody and ligand binding studies. One clone, 3H3, was selected for membrane preparation.

(ii) Membrane preparation from cultured cells

All steps of the protocol are carried out at 4°C and with pre-cooled reagents. The cell pellet is resuspended in 10 volumes of buffer A2 containing 50mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.40) supplemented with 10e-4M leupeptin (acetyl-leucyl-leucyl-arginal; Sigma L2884), 25µg/ml bacitracin (Sigma B0125), 1mM ethylenediamine tetra-acetic acid (EDTA), 1mM phenylmethylsulfonyl fluoride (PMSF) and 2x10e-6M pepstain A (Sigma). The cells are then homogenised by 2 x 15 second bursts in a 1 litre glass Waring blender, followed by centrifugation at 500g for 20 minutes. The supernatant is then spun at 48,000g for 30 minutes. The pellet is resuspended in 4 volumes of buffer A2 by vortexing for 5 seconds, followed by homogenisation in a Dounce homogeniser (10-15 strokes). At this point the preparation is aliquoted into polypropylene tubes and stored at -70°C.

Compounds of the invention may be tested for in vitro biological activity in accordance with the following assays:

(i) Histamine H3 binding assay

For each compound being assayed, in a white walled clear bottom 96 well plate, is added:-

- (a) 10µl of test compound (or 10µl of iodophenpropit (a known histamine H3 antagonist) at a final concentration of 10mM) diluted to the required concentration in 10% DMSO;
 - (b) 10µl ¹²⁵I 4-[3-(4-iodophenylmethoxy)propyl]-1H-imidazolium (iodoproxyfan) (Amersham; 1.85MBq/µl or 50µCi/ml; Specific Activity ~2000Ci/mmol) diluted to 200pM in assay buffer (50mM Tris(hydroxymethyl)aminomethane buffer (TRIS) pH 7.4, 0.5mM ethylenediamine tetra-acetic acid (EDTA)) to give 20pM final concentration; and
 - (c) 80µl bead/membrane mix prepared by suspending Scintillation Proximity Assay (SPA) bead type WGA-PVT at 100mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 80µl which contains 7.5µg protein and 0.25mg bead per well
- mixture was pre-mixed at room temperature for 60 minutes on a roller.

The plate is shaken for 5 minutes and then allowed to stand at room temperature for 3-4 hours prior to reading in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data was analysed using a 4-parameter logistic equation.

5 **(II) Histamine H3 functional antagonist assay**

For each compound being assayed, in a white walled clear bottom 96 well plate, is added:-

- 10 (a) 10 μ l of test compound (or 10 μ l of guanosine 5'- triphosphate (GTP) (Sigma) as non-specific binding control) diluted to required concentration in assay buffer (20mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) + 100mM NaCl + 10mM MgCl₂, pH7.4 NaOH);
- 15 (b) 60 μ l bead/membrane/GDP mix prepared by suspending wheat germ agglutinin-polyvinyltoluene (WGA-PVT) scintillation proximity assay (SPA) beads at 100mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 60 μ l which contains 10 μ g protein and 0.5mg bead per well – mixture is pre-mixed at 4°C for 30 minutes on a roller and just prior to addition to the plate, 10 μ M final concentration of guanosine 5' diphosphate (GDP) (Sigma; diluted in assay buffer) is added;
- 20 The plate is incubated at room temperature to equilibrate antagonist with receptor/beads by shaking for 30 minutes followed by addition of:
- 20 (c) 10 μ l histamine (Tocris) at a final concentration of 0.3 μ M; and
- 20 (d) 20 μ l guanosine 5' [γ 35-S] thiotriphosphate, triethylamine salt (Amersham; radioactivity concentration = 37kBq/ μ l or 1mCi/ml; Specific Activity 1160Ci/mmol) diluted to 1.9nM in assay buffer to give 0.38nM final.

25 The plate is then incubated on a shaker at room temperature for 30 minutes followed by centrifugation for 5 minutes at 1500 rpm. The plate is read between 3 and 6 hours after completion of centrifuge run in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data is analysed using a 4-parameter logistic equation. Basal activity used as minimum i.e. histamine not added to well.


30 **Results**

The compounds of Examples E1-8 were tested in the histamine H3 functional antagonist assay and exhibited antagonism > 6.5 pK_b. More particularly, the compound of Example 8 exhibited antagonism > 9.5 pK_b.

35

CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 represents $-C_{3-7}$ cycloalkyl optionally substituted by C_{1-3} alkyl;

R^2 represents hydrogen, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, -aryl, -heterocyclyl, -heteroaryl, $-C_{3-8}$ cycloalkyl-Y- C_{3-8} cycloalkyl, $-C_{3-8}$ cycloalkyl-Y-aryl, $-C_{3-8}$ cycloalkyl-Y-heteroaryl, $-C_{3-8}$ cycloalkyl-Y-heterocyclyl, -aryl-Y- C_{3-8} cycloalkyl, -aryl-Y-aryl, -aryl-Y-heteroaryl, -aryl-Y-heterocyclyl, -heteroaryl-Y- C_{3-8} cycloalkyl, -heteroaryl-Y-aryl, -heteroaryl-Y-heteroaryl, -heteroaryl-Y-heterocyclyl, -heterocyclyl-Y- C_{3-8} cycloalkyl, -heterocyclyl-Y-aryl, -heterocyclyl-Y-heteroaryl, -heterocyclyl-Y-heterocyclyl;

X represents a bond, CO, SO_2 , $CONR^5$ or COO ;

Y represents a bond, C_{1-6} alkyl, CO, CONH, NHCO, O, SO_2 , SO_2NH or $NHSO_2$;

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

R^4 and R^5 independently represent hydrogen, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, -aryl, -heterocyclyl or -heteroaryl;

n is 0, 1 or 2;

wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2 , R^3 and R^4 may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl, pentafluoroethyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, $-R^5$, $-CO_2R^5$, $-COR^5$, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl, aroyl C_{1-6} alkyl, aryl C_{1-6} alkanoyl, or a group $-NR^6R^7$, $-C_{1-6}$ alkyl- NR^6R^7 , $-C_{3-8}$ cycloalkyl- NR^6R^7 , $-CONR^6R^7$, $-NR^6COR^7$, $-NR^6SO_2R^7$, $-OCONR^6R^7$, $-NR^6CO_2R^7$, $-NR^5CONR^6R^7$ or $-SO_2NR^6R^7$ (wherein R^5 , R^6 and R^7 independently represent hydrogen, C_{1-6} alkyl, $-C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl- C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or $-NR^6R^7$ may represent a nitrogen containing heterocyclyl group, wherein said R^5 , R^6 and R^7 groups may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, =O or trifluoromethyl);

or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E8 or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

4. A compound as defined in claim 1 or claim 2 for use in therapy.

5. A compound as defined in claim 1 or claim 2 for use in the treatment of neurological diseases.

6. Use of a compound as defined in claim 1 or claim 2 in the manufacture of a medicament for the treatment of neurological diseases.

7. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

PCT/EP2004/014380



PW

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.